olaparib

Olaparib Phase 3 Development Discontinued by AstraZeneca

(January 1, 2012) In a surprise announcement, AstraZeneca put out a press release in late December announcing the cancellation Phase 3 development for olaparib. The official reason given for abandoning development was as follows: “The decision to discontinue olaparib’s development in serous ovarian cancer was made following a review of an interim analysis of a …

Olaparib Phase 3 Development Discontinued by AstraZenecaRead More »

PARP Inhibitors Slow Tumor Growth in 85% of Advanced Breast Cancer Patients

Editor’s Note: The following is a press release based on a recent PARP Inhibitor study/trial. We have not edited this press release in any way. The source of the press release is Penn Medicine. It is our editorial policy to always let you know when something we publish is a press release and who the …

PARP Inhibitors Slow Tumor Growth in 85% of Advanced Breast Cancer PatientsRead More »

Olaparib Parp Inhibitors Inherited Ovarian Cancer Results

(Ovarian Cancer Parp Inhibitors Research) The experimental cancer drug olaparib, a drug in the promising class of drugs known as PARP Inhibitors,  produced promising results in patients with ovarian cancer linked to an inherited BRCA1 or BRCA2 gene mutation. The trial results were published in the Journal of Clinical Oncology on April 19th, 2010. Scientists at The Institute …

Olaparib Parp Inhibitors Inherited Ovarian Cancer ResultsRead More »